Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopulegol SCHEMBL8814863 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL12044788 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL8814281 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL12451192 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL8815381 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL8815146 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL20903638 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL20903648 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL20681722 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL43859 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279878-B | Cleaning composition | 联合利华知识产权控股有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-117716009-A | Composition for reducing off-flavors | 联合利华知识产权控股有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-117321183-A | Composition for reducing off-flavors | 联合利华知识产权控股有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-116568267-A | Compositions comprising (bio) -alkanediol and cooling agent | 西姆莱斯股份公司 | 2023-08-08 | — | — | CN | claimed |
| EP-3820945-B1 | SURFACE-REACTED CALCIUM CARBONATE FOR STABILIZING MINT OIL | OMYA INT AG (CH) | 2023-03-01 | — | — | EP | claimed |
| CN-112272688-B | Surface-reacted calcium carbonate for stabilizing peppermint oil | OMYA国际股份公司 | 2022-01-28 | — | — | CN | claimed |
| CN-122005326-A | Oral care composition comprising gel network and potassium nitrate | 宝洁公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4723887-A1 | METHODS AND COMPOUNDS | University of Leicester (GB) | 2026-04-15 | — | — | EP | disclosed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4563705-A1 | BIOCATALYTIC STEREOCONTROLLED PRODUCTION OF 1-(R)-CIS-PMD | Universität Stuttgart (DE) | 2025-06-04 | — | — | EP | disclosed |
| US-7402608-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-07-22 | — | — | US | disclosed |
| US-7402608-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-07-22 | — | — | US | disclosed |
| US-20080167504-A1 | reacting a bis(diarylphenol) ligand with an alkylaluminum compound and/or a complex aluminum hydride; producing isopulegol by cyclization of citronellal in the presence of diarylphenoxyaluminum compounds as catalysts | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167504-A1 | reacting a bis(diarylphenol) ligand with an alkylaluminum compound and/or a complex aluminum hydride; producing isopulegol by cyclization of citronellal in the presence of diarylphenoxyaluminum compounds as catalysts | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-0621892-B1 | USE OF FURANONES AS SCENTING INGREDIENTS | FIRMENICH & CIE (CH) | 1998-07-08 | — | — | EP | disclosed |
| US-5464824-A | Odors and perfumed articles | FIRMENICH SA (CH) | 1995-11-07 | — | — | US | disclosed |
| WO-1994012143-A2 | USE OF FURANONES AS SCENTING INGREDIENTS | FIRMENICH SA (CH) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167504-A1 | reacting a bis(diarylphenol) ligand with an alkylaluminum compound and/or a complex aluminum hydride; producing isopulegol by cyclization of citronellal in the presence of diarylphenoxyaluminum compounds as catalysts | ACSL3, ACSL1, ACSL5 | TRPA1 42/4885TRPM8 69/4885CA1 120/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | TRPA1 365/4885TRPM8 436/4885CA1 4429/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | TRPA1 41/4885TRPM8 52/4885CA1 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.